Split-Fill Program for Oncology Oral Medications Is Cost-Saving

February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

The discontinuation of oral oncology medications before the full-month supply has been finished results in medication waste, leading to increased costs for patients and for payers. Split fills allow for a 14- to 16-day supply for oral oncology medications rather than a full 28- to 30-day supply. Researchers compared the discontinuation rates, patient-reported adverse events, estimated pharmacy costs, and potential waste in patients with pharmacy benefit designs that included a split-fill option with patients who did not have this option (Staskon FC, et al. J Oncol Pract. 2019;15:e856-e862).

This retrospective cohort study included patients who were new to therapy with one of the 11 split-fill oncology oral medications within the managed program, between September 2015 and August 2017. Patients using split-fill and non–split-fill medications were matched by age, sex, state census areas, index medication, start date, and the use of >1 medication. The study included 2363 patients within the managed program who met the selection criteria for the 11 medications, and 671 patients from each group were matched.

The per-month medication discontinuation rates were assessed for each group. The monthly utilization trends indicated a significantly higher persistency rate for the split-fill cohort than the non–split-fill cohort in the second month (71.6% vs 67%, respectively; P <.001). Payers participating in a split-fill program had mean average wholesale price (AWP) savings of $2147.60 at 1 month and $928.60 at 6 months. Based on modeled waste, payers without a split-fill program could expect to save $2646.74 AWP monthly if they moved to the split-fill option.

Both cohorts had similar rates of adverse effects (55.3% for the split-fill cohort vs 56.4% for the non–split-fill cohort). The time until the first reported adverse effect trended toward being earlier for the split-fill group, but not significantly earlier.

“Even after noted modifications were made for new therapies, the split-fill patient managed component had lower discontinuation rates, significantly reduced pharmacy costs, and reduced potential wastage,” concluded the researchers. “By adopting a split-fill option, insurance payers have a means of reducing the pharmacy cost for new oncolytic therapy drugs, providing additional benefits to patients regarding copay, and addressing adverse events.”

Related Articles

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: